We are a cell therapy company focused on immunotherapy. Since our inception, we have been involved with the development of proprietary immune system management technology licensed from Yeda Research & Development Company Limited (“Yeda”), the commercial arm of the Weizmann Institute of Technology, Israel.
Company profile
Ticker
CLCS
Exchange
Website
CEO
Itamar Shimrat
Employees
Incorporated
Location
Fiscal year end
Sector
Industry (SIC)
Former names
TICKET TO SEE, INC.
SEC CIK
CLCS stock data
Latest filings (excl ownership)
10-Q
2022 Q3
Quarterly report
8 Dec 22
10-Q
2022 Q2
Quarterly report
2 Dec 22
10-Q
2022 Q1
Quarterly report
2 Nov 22
8-K
Departure of Directors or Certain Officers
21 Jul 22
NT 10-Q
Notice of late quarterly filing
12 May 22
8-K
Departure of Directors or Certain Officers
6 May 22
10-K
2021 FY
Annual report
15 Apr 22
NT 10-K
Notice of late annual filing
31 Mar 22
8-K
Entry into a Material Definitive Agreement
11 Mar 22
10-Q
2021 Q3
Quarterly report
15 Nov 21
Latest ownership filings
Financial summary
| Quarter (USD) | Sep 22 | Jun 22 | Mar 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 65.94 k | 65.94 k | 65.94 k | 65.94 k | 65.94 k | 65.94 k |
| Cash burn (monthly) | (no burn) | 94.41 k | 338.68 k | 307.45 k | 362.22 k | 239.55 k |
| Cash used (since last report) | n/a | 369.01 k | 1.32 mm | 1.20 mm | 1.42 mm | 936.27 k |
| Cash remaining | n/a | -303.07 k | -1.26 mm | -1.14 mm | -1.35 mm | -870.33 k |
| Runway (months of cash) | n/a | -3.2 | -3.7 | -3.7 | -3.7 | -3.6 |
Institutional ownership, Q1 2021
| 13F holders | Current |
|---|---|
| Total holders | 0 |
| Opened positions | 0 |
| Closed positions | 0 |
| Increased positions | 0 |
| Reduced positions | 0 |
| 13F shares | Current |
|---|---|
| Total value | 0.00 |
| Total shares | 0.00 |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|
Recent insider trades
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 9 Aug 21 | Darlene Soave | Warrant (Option to buy) Common Stock | Other | Acquire J | No | No | 1.25 | 800,000 | 1.00 mm | 800,000 |